Last updated: February 13, 2026
Product Overview
NDC 00075-0626 indicates a specific drug product, which is Aflibercept Injection, 4 mg/mL, 100 mcg/0.1 mL (brand name Eylea). Approved by the FDA for numerous indications, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular diseases.
Market Size and Growth Drivers
The global retinal disease treatment market, primarily comprising treatments such as aflibercept, is projected to grow continuously. Key factors include:
- Aging population: The number of individuals over 65 increases globally, particularly in North America, Europe, and parts of Asia.
- Rising prevalence of diabetic retinopathy and AMD: Estimated 200 million people worldwide with diabetic retinopathy and over 170 million with AMD by 2025.
- Advancement in treatment options: Aflibercept's approval for multiple indications creates a broad revenue stream.
The global retinal disease therapeutics market was valued at approximately USD 4.5 billion in 2022 and is expected to grow at a CAGR of around 6% through 2028 [1].
Competitive Landscape
Major competitors include:
- Ranibizumab (Lucentis): Market share largely replaced by aflibercept in some indications due to dosing convenience and efficacy.
- Brolucizumab (Beovu): Recently approved withpotential as a competitor.
- Bevacizumab: Used off-label, lower-cost alternative.
Market leaders such as Regeneron (Eylea) and Roche (Lucentis) dominate with significant R&D investments.
Pricing Analysis
Current list prices in the U.S.:
- Eylea (NDC 00075-0626): Approximate wholesale acquisition cost (WAC) of USD 1,950 per 2-mg dose [2].
Pricing comparisons:
| Drug |
Dose |
Approximate Price |
Notes |
| Eylea |
2 mg |
USD 1,950 |
Per intravitreal injection |
| Lucentis |
0.5 mg |
USD 1,950 |
Similar per dose |
| Beovu |
4 mg |
USD 2,000 |
Slightly higher |
| Off-label Bevacizumab |
1.25 mg |
USD 50-100 |
Lower-cost alternative |
Pricing Trends & Future Projections
- Price Stability: Current prices for aflibercept have remained relatively stable since 2020, with some minor adjustments due to inflation and negotiated discounts by payers.
- Potential Price Decreases: Introduction of biosimilars or generic formulations could pressure prices downward within 2-3 years, especially outside the U.S.
- Pricing in Different Markets: Europe and Asia typically see lower prices due to regional price controls. In China, the treatment costs can be 50-70% lower.
Regulatory and Market Impact
FDA approvals expanding the use of aflibercept for additional indications can sustain or elevate revenue. Disruptions such as biosimilar entry or governmental price negotiations can influence future prices.
Market Penetration and Revenue Projections
- Estimated global revenue for aflibercept in ophthalmology: USD 2.4 billion in 2022.
- Expected growth driven by expanded indications, particularly in emerging markets.
- Regeneron’s pipeline and pipeline competitors could influence market share, with Regeneron maintaining approximately 60% of the market share in 2022 [3].
Risks and Challenges
- Patent expirations could lead to generic biosimilar competition.
- Payer delays or restrictions on reimbursement.
- Development of oral or alternative therapies reducing reliance on injections.
Key Financial Implications
- For investors and R&D strategists, current price levels suggest strong revenue sustainability but face threats from biosimilar competition in the next 3-5 years.
- Companies should monitor patent expiration timelines; Regeneron’s key patents expire in 2025-2027, which could modulate pricing strategies.
Key Takeaways
- NDC 00075-0626 (Eylea) remains a dominant, high-priced treatment for retinal diseases with stable pricing trends, though biosimilar entry could pressure prices.
- The market is growing due to demographic shifts and expanding indications, with forecasted revenues rising to USD 4 billion globally by 2028.
- Price projections suggest a potential decrease in 2-3 years, especially outside the U.S., due to biosimilars and payer negotiations.
- Competition from Lucentis and newer agents such as Brolucizumab could influence market share.
- Regulatory and patent landscapes remain critical determinants of future pricing trajectory.
FAQs
1. When are biosimilar versions of aflibercept expected to enter the market?
Biosimilar development has progressed, but FDA approval timelines vary. Biosimilars may reach the U.S. market by 2025-2026, subject to regulatory approvals.
2. How does the pricing of Eylea compare with off-label bevacizumab?
Eylea costs approximately USD 1,950 per dose, whereas off-label bevacizumab costs around USD 50–100 per dose, significantly lower but with different regulatory and safety considerations.
3. What factors influence the pricing stability of aflibercept?
Pricing maintains stability due to patent protections, brand recognition, and consistent demand for treatment. Price reductions are anticipated upon patent expiration or biosimilar introduction.
4. How do reimbursement policies affect market prices?
Reimbursement levels set by Medicare, Medicaid, and private insurers influence net prices and can lead to negotiated discounts or restrictive coverage.
5. What are the implications of expanding indications for aflibercept?
Additional indications can extend revenue streams and justify higher prices initially; however, they also increase regulatory complexity and market competition.
References
[1] MarketsandMarkets, "Retinal Disease Therapeutics Market," 2022.
[2] Drug Price Database, "Aflibercept (Eylea) Wholesale Prices," 2023.
[3] EvaluatePharma, "Retinal Therapeutics Market Share," 2022.
